Elacestrant Dihydrochloride is a selective estrogen receptor degrader (SERD) and anticancer agent utilized to treat ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer in patients… Read more
Elacestrant Dihydrochloride is a selective estrogen receptor degrader (SERD) and anticancer agent utilized to treat ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer in patients who have experienced disease progression following prior endocrine therapy. As a critical component in the pharmaceutical development and manufacturing process, this category encompasses high-quality reference standards for Elacestrant Dihydrochloride API. These materials, including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope labelled compounds, are essential for rigorous analytical testing, impurity profiling, and method validation. Pharmaceutical laboratories rely on these characterized compounds to ensure the accuracy of identification and quantification protocols throughout the drug substance lifecycle. By providing precise reference points for complex analytical workflows, these materials support comprehensive quality control measures necessary to maintain the safety and efficacy of the final therapeutic product in accordance with stringent regulatory standards.